60 Degrees Pharmaceuticals
SXTP
5 hedge funds and large institutions have $36.1K invested in 60 Degrees Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
1.01% less ownership
Funds ownership: 2.04% → 1.03% (-1%)
17% less funds holding
Funds holding: 6 → 5 (-1)
34% less capital invested
Capital invested by funds: $54.8K → $36.1K (-$18.7K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.63K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$40.5K |
| 2 |
SHF
Safe Harbor Fiduciary
Pensacola,
Florida
|
-$506 |
SXTP Hedge Fund Activity: Q2 2025 in Review
5 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in 60 Degrees Pharmaceuticals (SXTP) for Q2 2025, worth a combined $36.1K — down 34% from $54.8K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SXTP and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.63K. The largest seller was UBS Group, cutting an estimated $40.5K.
- 5 institutional investors held 60 Degrees Pharmaceuticals (SXTP) as of Q2 2025, down from 6 in Q1 2025.
- Funds reported $36.1K of 60 Degrees Pharmaceuticals stock for Q2 2025, down 34% quarter-over-quarter.
- 0 funds opened new 60 Degrees Pharmaceuticals positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest 60 Degrees Pharmaceuticals buyer in Q2 2025 was Tower Research Capital (TRC), an estimated $2.63K added.
- The largest 60 Degrees Pharmaceuticals seller in Q2 2025 was UBS Group, an estimated $40.5K sold.
Based on aggregated 13F filings for Q2 2025.